PathoVax, a biotech start-up originating from Johns Hopkins University, is dedicated to advancing healthcare through the commercialization of RGVax, a novel vaccine technology. Their core mission is to develop innovative solutions to combat infectious diseases, ultimately improving global health outcomes. PathoVax focuses on leveraging cutting-edge bioscience to create effective and accessible vaccines, targeting markets that are in critical need of advanced medical interventions.

Notable affiliations include its strong ties to Johns Hopkins University, which provides a robust foundation of research and expertise. The company has garnered attention from prominent investors in the biotech sector, though specific names are not publicly disclosed. Key achievements include the development and initial commercialization of RGVax, positioning PathoVax as a promising player in the vaccine industry. The impact of their work is significant, with the potential to address unmet medical needs and contribute to the prevention of infectious diseases worldwide.